What's New in PAH?
Program Themes
Important Advances in PAH
Evolution of Clinical Trials in PAH
Challenges With Clinical Trial Design
Growing Use of Combination Therapy
AMBITION Trial: Ambrisentan and Tadalafil in Patients With PAH
Trends in Treatment Options for a Newly Diagnosed Patient in WHO FC II or III
AMBITION Trial: First Adjudicated Clinical Failure by Subgroups
Determinants of Prognosis in PAH
GRIPHON Trial Design
GRIPHON Trial Clinical Efficacy
GRIPHON Trial Treatment Effect by Subgroup
Effective Communication With Patients
Pharmacologic Agents for PAH 3 Pathways
Initial Triple Therapy
Opportunity to Incorporate PROs
PAH-SYMPACT
World Symposium on Pulmonary Hypertension, February 2018
Perspectives of 2 Experts
Concluding Remarks
Abbreviations